Affiliation:
1. Department of Traditional Chinese Medicine Beijing Electric Power Teaching Hospital Capital Medical University Beijing China
2. Department of Oncology Beidahuang Industry Group General Hospital Harbin Heilongjiang China
Abstract
AbstractThe patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post‐hepatitis B cirrhosis during the period of compensated liver function. Following a 7‐month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha‐fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.